B-Cell Depletion Salvage Therapy in Rapidly Progressive Dermatomyositis Related Interstitial Lung Disease.

Abstract

Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with idiopathic inflammatory myopathies (IIM). Glucocorticoids are the initial standard treatment. However, many patients fail to respond and continue to progress despite treatment with high dose glucocorticoids. The efficacy of rituximab has been suggested in case reports and case series of refractory antisynthetase (AS) syndrome, but data on patients without auto-antibodies or with rapidly progressive ILD are scarce. We report a case of rapidly progressive dermatomyositis (DM) associated ILD treated successfully with B-cell depletion therapy.

• Authors: Khaled Eissa, Jaime Palomino
• Journal: The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society (J La State Med Soc) 2016 May-Jun Vol. 168 Issue 3 Pg. 99-100 ISSN: 0024-6921 [Print] United States
• PMID: 27389378 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunologic Factors
• Rituximab

Topics

• Aged
• B-Lymphocytes (drug effects)
• Dermatomyositis (drug therapy)
• Humans
• Immunologic Factors (administration & dosage)
• Lung Diseases, Interstitial (complications)
• Male
• Rituximab (administration & dosage)
• Salvage Therapy
• Tomography, X-Ray Computed